ONCO Form 4: Director Meier Receives Restricted Shares; Vesting Extended to 2026
Rhea-AI Filing Summary
Thomas Meier, a director of Onconetix, Inc. (ticker: ONCO), reported changes to his restricted stock holdings on Form 4 dated 08/15/2025. The filing shows a modification of a previously granted restricted stock award (originally granted 09/26/2024) that changes the vesting date from August 31, 2025 to August 31, 2026, conditioned on continued service as a non-employee director through that date. The filing also reports a restricted stock award of 618 shares that will vest in full on August 31, 2026, and a reported amount of 39 shares related to the modified award, with 657 shares shown as beneficially owned following the transactions (amounts presented on a post 1-for-85 reverse split basis).
The filing discloses the issuer effected a 1-for-85 reverse split on June 13, 2025 and states all share amounts are post-split. No cash consideration is reported for the awards.
Positive
- New restricted stock award of 618 shares granted that vests in full on August 31, 2026, subject to continued service
- Disclosure reflects post-split amounts after the 1-for-85 reverse split, improving clarity for investors
Negative
- Original restricted award vesting was delayed from August 31, 2025 to August 31, 2026, extending the service condition
Insights
TL;DR: Director received new restricted shares while a prior award's vesting was pushed one year, resulting in 657 shares beneficially owned post-split.
The filing reports a new restricted stock award of 618 shares and a modification of an earlier award (reported as 39 shares), producing 657 post-split shares beneficially owned. Both awards vest on August 31, 2026, subject to continued board service. The actions are equity compensation adjustments rather than open-market trading and show no cash price paid. The disclosed 1-for-85 reverse split materially changed share counts and is properly reflected.
TL;DR: Vesting terms were extended for an existing award while a new award was granted; both require continued director service through 8/31/2026.
From a governance perspective, the modification delaying the original award's vesting date to 8/31/2026 aligns incentive period with continued service criteria. The simultaneous grant of additional restricted shares ties compensation to future board service. The Form 4 provides clear disclosure of the modification, grant, and the reverse split adjustment, fulfilling Section 16 reporting obligations.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Other | Common Stock | 39 | $0.00 | -- |
| Grant/Award | Common Stock | 618 | $0.00 | -- |
Footnotes (1)
- Represents a restricted stock award originally granted to the Reporting Person on September 26, 2024 pursuant to the Issuer's 2022 Equity Incentive Plan, as amended ("2022 Plan" and the grant on such date, the "Original Award"). On August 15, 2025, the Original Award was modified to change the vesting terms, such that the award, which was to vest in full on August 31, 2025, was changed to vest in full on August 31, 2026, so long as the Reporting Person continues to serve as a non-employee director of the Issuer until such date. Except as set forth herein, the Original Award remains unmodified. On June 13, 2025, the Issuer effected a 1-for-85 reverse split of its Common Stock. The amounts set forth herein are presented on a post-split basis. Represents a restricted stock award granted to the Reporting Person pursuant to the 2022 Plan. The award will vest in full on August 31, 2026 so long as the Reporting Person continues to serve as a non-employee director of the Issuer until such date.
